In this respect, large-scale genomic studies indicate that mutations of the Hsh155/SF3B1 protein recur in hematologic malignancies (i.e., myelodysplastic syndromes (MDS) [13], chronic lymphocytic leukemia [14], and chronic myelomonocytic leukemia [15], and less commonly in solid tumors [7]). Here, SF3B1 is linked to hematologic disorder.